Those who post on this board may already be quite aware of this, but there is a interesting detail about the Abbott deal that I have never focused on before. Abbott actually obtained "worldwide, semi-exclusive rights to commercialize products using BioCurex's RECAF technology". The press releases at the time, and even BioCurex's November 9, 2005 SB-2/A SEC filing uses that exact wording to describe Abbott's license. So Abbott's license is actually broader than Abbott's stated goal "to further develop this technology, incorporating it into future tests on our Architect system, for use in cancer diagnosis and monitoring." Those future tests obviously involve serum RECAF tests. But the exact wording of Abbott's semi-exclusive license appears to include BioCurex's imaging and Histo-RECAF technology. kag
